Lenalidomide, dexamethasone and alemtuzumab or ofatumumab in high-risk chronic lymphocytic leukaemia: final results of the NCRI CLL210 trial.

Pettitt AR., Jackson R., Cicconi S., Polydoros F., Yap C., Dodd J., Bickerstaff M., Stackpoole M., Khan UT., Carruthers S., Oates M., Lin K., Coupland SE., Menon G., Kalakonda N., McCarthy H., Bloor A., Schuh A., Duncombe A., Dearden C., Fegan C., Kennedy B., Walewska R., Marshall S., Fox CP., Hillmen P.

DOI

10.3324/haematol.2019.230805

Type

Journal article

Journal

Haematologica

Publication Date

01/12/2020

Volume

105

Pages

2868 - 2871

Keywords

Alemtuzumab, Antibodies, Monoclonal, Humanized, Antineoplastic Agents, Dexamethasone, Humans, Lenalidomide, Leukemia, Lymphocytic, Chronic, B-Cell, Treatment Outcome

Permalink Original publication